Director, Drug Product Development

Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.

It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.

Led by Tassos Giannakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.

We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.

At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families , we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic —leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn , we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.

These values are the foundation of our work, empowering us to make a real difference, every day.

About this role:

Kardigan is seeking a Director, CMC Drug Product Development, to support development of late phase projects. This role will report directly into the Head of Drug Product Development.

In this role, you will be responsible for the leadership, management and oversight of outsourced formulation development, process development, scale-up, validation, technology transfer, and file launch activities required to support Kardigan’s portfolio of small molecules and oligonucleotides. This hands‑on role will lead drug product development, scale-up, technology transfer, registration and validation batches, authoring of Module 3 documents and working closely with CDMOs to support inspection readiness. This is a 4‑day, onsite position, based in South San Francisco or Princeton NJ.

Responsibilities:

• Lead drug product development for both early phase and late phase assets.
• A member of CMC project teams accountable for all drug product development and manufacturing activities to support both early and late phase projects.
• Manage and oversee outsourced formulation development, process development, scale‑up, validation, technology transfer, and clinical/commercial drug product manufacturing to support early and late Phase clinical development programs and future commercial supply.
• Ensure formulation and drug products meet the target product profile necessary to enable the successful commercialization of the product.
• Develop phase‑appropriate pharmaceutical project plans, participate in CDMO selection, and manage successful execution of these plans consistent with corporate timelines and compliant with cGMP/regulatory requirements and expectations.
• Develop, review, and approve manufacturing batch records, manage internal batch release activities.
• Establish appropriate drug product specifications and stability studies in partnership with Analytical, Quality, CDMOs, Regulatory, and other subject matter experts to support intended use.
• Write and review protocols, reports, and drug product sections for regulatory documents.
• Contribute to product investigations and conduct root cause analysis.
• Interface and coordinate activities with drug substance, analytical development, regulatory affairs, quality assurance, and product supply to ensure on time release and uninterrupted supply of drug product.
• Collaborate with legal and procurement to review contract terms and execution of agreements.
• Keep up with the latest regulatory and cGMP guidance and awareness of state‑of‑the‑art manufacturing practices.
• Monitor status of CDMO capacity, manage risks and make recommendations to Kardigan’s leadership team.
• Manage the negotiation of contracts broadly applicable to drug product manufacturing. Ownership of the contract deliverables and obligations.

Qualifications and Experience:

• S. or PhD in pharmaceutical sciences, chemical engineering, or a related discipline. Advanced degree preferred.
• Minimum 10 years' experience within pharmaceutical CMC development and Technical Operations. Experience with both sterile and oral products, including device development is preferred.
• Sound knowledge of formulation development, process engineering and plant operations.
• Demonstrated experience with drug product process development, scale‑up, and optimization from R&D through commercialization, including an understanding of the interdependencies of functional groups and working closely with external CDMOs.
• Significant experience in working with global health authorities, IND, IMPD, NDA, MAA etc.
• Experience with process validation and continuous process improvement.
• Ideally experience with commercializing small molecule drug products.
• Extensive knowledge of regulated manufacturing, GMP, GCP and quality systems.
• Creative/innovative/problem solver that actively drives progress.
• Ability to manage multiple projects in a fast‑paced environment.
• Strong interpersonal communication skills, proven ability to build and maintain collaborative, effective internal and external relationships.
• Excellent written, oral communication, and presentation skills along with the ability to communicate effectively with senior management.
• Ability to effectively collaborate in a dynamic, cross‑functional matrix environment.

Exact Compensation may vary based on skills, experience and location.

$204,000 - $266,000 USD

As set forth in Kardigan’s Equal Employment Opportunity policy,we do not discriminate on the basis of any protected group status under any applicable law.

Voluntary Self‑Identification

For government reporting purposes, we ask candidates to respond to the below self‑identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file.

Voluntary Self‑Identification of Disability

Form CC-305 Page 1 of 1 OMB Control Number  Expires 04/30/2026

Why are you being asked to complete this form?

We are a federal contractor or subcontractor. The law requires us to provide equal employment opportunity to qualified people with disabilities. We have a goal of having at least 7% of our workers as people with disabilities. The law says we must measure our progress towards this goal. To do this, we must ask applicants and employees if they have a disability or have ever had one. People can become disabled, so we need to ask this question at least every five years.

Completing this form is voluntary, and we hope that you will choose to do so. Your answer is confidential. No one who makes hiring decisions will see it. Your decision to complete the form and your answer will not harm you in any way. If you want to learn more about the law or this form, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at

How do you know if you have a disability?

A disability is a condition that substantially limits one or more of your “major life activities.” If you have or have ever had such a condition, you are a person with a disability. Disabilities include, but are not limited to:

• Alcohol or other substance use disorder (not currently using drugs illegally)
• Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, HIV/AIDS
• Blind or low vision
• Cancer (past or present)
• Cardiovascular or heart disease
• Celiac disease
• Cerebral palsy
• Deaf or serious difficulty hearing
• Diabetes
• Disfigurement, for example, disfigurement caused by burns, wounds, accidents, or congenital disorders
• Epilepsy or other seizure disorder
• Gastrointestinal disorders, for example, Crohn's Disease, irritable bowel syndrome
• Intellectual or developmental disability
• Mental health conditions, for example, depression, bipolar disorder, anxiety disorder, schizophrenia, PTSD
• Missing limbs or partially missing limbs
• Mobility impairment, benefiting from the use of a wheelchair, scooter, walker, leg brace(s) and/or other supports
• Nervous system condition, for example, migraine headaches, Parkinson’s disease, multiple sclerosis (MS)
• Neurodivergence, for example, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, dyslexia, dyspraxia, other learning disabilities
• Partial or complete paralysis (any cause)
• Pulmonary or respiratory conditions, for example, tuberculosis, asthma, emphysema
• Short stature (dwarfism)
• Traumatic brain injury

PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.

#J-18808-Ljbffr